In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

Por Laukkanen, S, Grönroos, T, Pölönen, P, Kuusanmäki, H, Mehtonen, J, Cloos, J, Ossenkoppele, G, Gjertsen, B, Øystein, B, Heckman, C, Heinäniemi, M, Kontro, M, Lohi, O
Publicado no Blood Cancer J (2017)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

Por Eldfors, S, Kuusanmäki, H, Kontro, M, Majumder, M M, Parsons, A, Edgren, H, Pemovska, T, Kallioniemi, O, Wennerberg, K, Gökbuget, N, Burmeister, T, Porkka, K, Heckman, C A
Publicado no Leukemia (2017)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

Por Pietarinen, P O, Pemovska, T, Kontro, M, Yadav, B, Mpindi, J P, Andersson, E I, Majumder, M M, Kuusanmäki, H, Koskenvesa, P, Kallioniemi, O, Wennerberg, K, Heckman, C A, Mustjoki, S, Porkka, K
Publicado no Blood Cancer J (2015)